Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Antibodies

An antibody, human antibody technology, applied in the direction of antibodies, antibody medical components, anti-inflammatory agents, etc., can solve problems such as lack of application

Inactive Publication Date: 2012-05-30
CANCER RES TECH LTD
View PDF25 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0025] Accordingly, the art remains lacking in anti-CCR4 antibodies that can be used in the safe and effective treatment of patients with disorders involving CCR4, including chronic administration, and presents challenges in developing such antibodies

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antibodies
  • Antibodies
  • Antibodies

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0683] Example 1: New Antibodies

[0684] Four human antibodies capable of specifically binding CCR4 have been identified. The single chain form of the antibody was cloned into the pHOG21 plasmid, which contains c-myc and 6 his-tagged epitopes. TG1 bacteria were transfected and scFv expression was induced with IPTG. Binding of purified scFv was confirmed by EasyCyte.

[0685] The nucleotide sequences of the heavy and light chains of the resulting cloned antibodies were sequenced. The antibodies were designated 17G, 9E, 11F, 10, 9E10J and 9E1D. The nucleotide and amino acid sequences of the light and heavy chains of 17G are in figure 1 shown in . The CDR domains of the light and heavy chains of 17G are shown in Table 1. The nucleotide and amino acid sequences of the light and heavy chains of 9E are in figure 2 shown in . The CDR domains of the light and heavy chains of 9E are shown in Table 2. The nucleotide and amino acid sequences of the light and heavy chains of...

Embodiment 2

[0690] Example 2: Binding of Anti-CCR4 Antibodies to Target Expressing Cells

[0691] To demonstrate the CCR4 specificity of the antibodies disclosed in Example 1 and to assess their binding affinities, IgG-forms of 17G and 9E and scFv 10 and 11F were used in flow cytometry for CCR4-internally transfected and non-CCR4-transfected HEK293T cells, DT40 cells and native CCR4 + CCRF-CEM cell line staining. As a positive control, an in-house cloned and expressed IgG form of KM3060var specific for an epitope present at positions 2-29 of the N-terminus of human CCR4 (EP1270595) was used. Anti-GFP antibody (raised against green fluorescent protein) or anti-VZN antibody (raised against varicella zoster virus) was used as negative controls (anti-GFP antibody was in scFv and IgG format, while anti-VAN was only in scFv format).

[0692] CCRF-CEM (acute lymphocytic leukemia, ATCC No. CCL-119), HEK293T / 17 (human kidney, ATCC No. CRL-11268), and DT40 (chicken lymphoma, ATCC No. CRL-2111) ...

Embodiment 3

[0700] Example 3: Anti-CCR4 Antibodies Interfering with Ligand Binding

[0701] To determine whether the anti-CCR4 antibody interferes with CCR4 ligand and receptor binding, MDCs (obtained from PeproTech EC Ltd., London, UK) were pre-incubated with CCR4-transfected DT40 cells prior to staining with scFv. As a negative control, KM3060var scFv (see Table 10 for sequence), which is specific for the N-terminal portion of human CCR4, was used. It was previously shown that the antibody KM3060 does not interfere with ligand-receptor binding (T Ishida et al. (2006) Specific Recruitment of CC Chemokine Receptor 4-Positive Regulatory T Cells in Hodgkin Lymphoma Fosters Immune Privilege, Cancer Res 66: (11): 5716-5722.). KM3060var corresponds to KM3060, but it is expressed in a different host cell, which may result in a difference in the sugar chain attached to this antibody.

[0702] CCR4+DT40 cells were harvested from the culture flask, washed twice with RPMI-1640 medium, and equal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
affinityaaaaaaaaaa
Login to View More

Abstract

The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and / or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.

Description

technical field [0001] The present invention relates generally to antibodies, CCR4 biology and related therapeutic fields. More specifically, the invention provides antibodies that bind to CCR4. Such anti-CCR4 antibodies have applications in the diagnosis and treatment of diseases and conditions associated with CCR4, such as imaging tumor blood vessels, treating cancer and treating viral and other infections, and inflammatory and immune diseases. The antibody-based compositions and methods of the invention also extend to the use of immunoconjugates and other therapeutic compositions, kits and methods. Background technique [0002] With more than 800 members, G protein-coupled receptors (GPCRs) represent the largest family of cell surface molecules involved in signaling, accounting for >2% of all genes encoded by the human genome. Members of the GPCR superfamily share a common membrane topology: an extracellular N-terminus, an intracellular C-terminus, and a seven-transm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/28
CPCA61K39/3955C07K16/2866C07K2317/565C07K2317/732C07K2317/622C07K2317/21A61K45/06C07K2316/96A61K2039/505C07K2317/41C07K2317/56C07K2317/92A61P1/04A61P1/16A61P3/10A61P9/10A61P11/00A61P11/02A61P11/06A61P13/12A61P15/00A61P17/00A61P17/04A61P17/06A61P19/02A61P19/06A61P21/00A61P25/00A61P27/14A61P27/16A61P29/00A61P31/00A61P31/04A61P31/12A61P31/18A61P35/00A61P35/02A61P37/00A61P37/02A61P37/04A61P37/06A61P37/08A61P43/00C07K2317/76C07K2317/33
Inventor 拉维尼娅·黛安娜·奇科尔塔什·贡纳松迪德里克·派于斯
Owner CANCER RES TECH LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com